Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 9:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 69 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Duloxetine 60 mg/day Clear all
Completed Phase 4 Interventional Results available

Duloxetine for Menopausal Depression

NCT01117857
View directory record Official record
Conditions
Depression, Menopause, Vasomotor Symptoms
Interventions
Duloxetine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 3 Interventional Results available

A Study of Duloxetine in Patients With Osteoarthritis Knee Pain

NCT00945945
View directory record Official record
Conditions
Osteoarthritis Knee Pain
Interventions
Duloxetine (DLX), Placebo (PLA)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years and older
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
10
States / cities
Montgomery, Alabama • Phoenix, Arizona • Spring Valley, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2011 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 4 Interventional Results available

Pain Response Evaluation of a Combined Intervention to Cope Effectively

NCT04395001
View directory record Official record
Conditions
Chronic Pain
Interventions
duloxetine, Web-based Cognitive Behavioral Therapy (CBT), Nurse-delivered Motivational Interviewing
Drug · Behavioral · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 65 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 3 Interventional

Duloxetine Compared With Placebo in the Prevention of Relapse in Generalized Anxiety Disorder

NCT00122863
View directory record Official record
Conditions
Anxiety Disorders
Interventions
Duloxetine Hydrochloride, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
19
States / cities
Sherman Oaks, California • Fort Myers, Florida • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2007 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 4 Interventional Results available

Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy

NCT02058693
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
mixed salts amphetamine
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 2 Interventional

Exercise Plus Duloxetine for Knee Osteoarthritis

NCT04111627
View directory record Official record
Conditions
Knee Osteoarthritis, Depression
Interventions
Aerobic exercise, Duloxetine
Behavioral · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
40 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 4 Interventional Results available

An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain

NCT00385671
View directory record Official record
Conditions
Diabetic Neuropathy, Painful
Interventions
duloxetine hydrochloride, pregabalin, gabapentin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
5
States / cities
Torrance, California • Cromwell, Connecticut • Staten Island, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2011 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 4 Interventional

The Use of Duloxetine for Cognition Improvement in Individuals With Mild Cognitive Impairment

NCT02590874
View directory record Official record
Conditions
Mild Cognitive Impairment, Depression
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
University of North Texas Health Science Center
Other
Eligibility
50 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 3 Interventional Results available

Duloxetine vs. Placebo in the Treatment of Osteoarthritis Knee Pain

NCT00433290
View directory record Official record
Conditions
Osteoarthritis Knee Pain
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Fort Myers, Florida • Edison, New Jersey • Lake Jackson, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2009 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 3 Interventional Results available

A Study for Patient With Chronic Low Back Pain

NCT00767806
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Chandler, Arizona • Cromwell, Connecticut • DeLand, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2010 · Synced Oct 1, 2026, 9:31 PM EDT
Recruiting Not applicable Interventional

Algorithm-informed Decision-making to Advance Pain Treatment

NCT07731750
View directory record Official record
Conditions
Chronic Low-back Pain
Interventions
Algorithmically informed randomization (taking into account phenotypes), Physical Therapy (PT) and Exercise, Cognitive-Behavioral Therapy for Pain (PRISM-CBT), mHealth Acupressure Self-Management:, Duloxetine
Device · Behavioral · Drug
Lead sponsor
University of Michigan
Other
Eligibility
25 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder

NCT00672620
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vortioxetine, Duloxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
38
States / cities
Beverly Hills, California • Irvine, California • Santa Ana, California + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 1, 2026, 9:31 PM EDT
Not yet recruiting Phase 4 Interventional

Personalized Analgesia Through Central Nervous System Engagement to Unlock Performance

NCT07759336
View directory record Official record
Conditions
Knee Osteoarthritis (Knee OA), Chronic Pain, Chronic Knee Pain
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
Benedict Alter
Other
Eligibility
45 Years to 80 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 1, 2026, 9:31 PM EDT
Terminated Phase 2 Interventional Results available

6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder

NCT01145755
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
AZD2066, Placebo, Duloxetine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
13
States / cities
Garden Grove, California • San Diego, California • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 3 Interventional Results available

Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder

NCT00105989
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Duloxetine, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
5
States / cities
Newport Beach, California • Sherman Oaks, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2009 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

NCT01309945
View directory record Official record
Conditions
Depression
Interventions
Duloxetine, Placebo matching with BMS-820836, BMS-820836, Placebo matching with Duloxetine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
889 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
55
States / cities
Little Rock, Arkansas • Arcadia, California • Encino, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)

NCT01360866
View directory record Official record
Conditions
Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions
OPC-34712, Escitalopram, Fluoxetine, Paroxetine CR, Sertraline, Duloxetine, Venlafaxine XR
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
2,944 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
93
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 90 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 4 Interventional Results available

A Study of Duloxetine in Major Depressive Disorder (MDD) and Associated Painful Symptoms

NCT01000805
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
16
States / cities
Beverly Hills, California • Sherman Oaks, California • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2012 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Duloxetine Versus Placebo in Patients Taking a Nonsteroidal Anti-inflammatory Drug (NSAID) for Knee Pain Due to Osteoarthritis

NCT01018680
View directory record Official record
Conditions
Osteoarthritis Knee Pain
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years and older
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
32
States / cities
Tucson, Arizona • Garden Grove, California • Long Beach, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2012 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 3 Interventional Results available

A Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome

NCT01237587
View directory record Official record
Conditions
Fibromyalgia
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
13 Years to 17 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
26
States / cities
Phoenix, Arizona • Loma Linda, California • National City, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2019 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 3 Interventional Results available

A Study in the Treatment of Children and Adolescents With Major Depressive Disorder

NCT00849693
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, fluoxetine, duloxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
7 Years to 17 Years
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
44
States / cities
Birmingham, Alabama • Dothan, Alabama • Little Rock, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT03434041
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine 56 mg, Esketamine 84 mg, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
Atlanta, Georgia • Shreveport, Louisiana • Gaithersburg, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 3 Interventional Results available

Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome

NCT00114127
View directory record Official record
Conditions
Anxiety Disorder
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Behavioral Effects of Drugs: Inpatient (36) (Alcohol, Duloxetine, and Methylphenidate)

NCT03575403
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Alcohol, Placebos, Duloxetine (60 MG), Methylphenidate, Duloxetine (30 MG)
Drug
Lead sponsor
Craig Rush
Other
Eligibility
21 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 1, 2026, 9:31 PM EDT